skip to primary navigationskip to content

Evan Group - Cathy Wilson

Catherine Helen Wilson

Position: Honorary Postdoctoral Teaching Associate

Joined the lab: October 2010

Background: I graduated from Cardiff University in 2000 with a B.Sc. (hons) in Zoology. Following my undergraduate studies I worked as a research technician in the Wound Healing Research Unit, University of Wales Collage of Medicine and in the Institute of Medical Genetics, Cardiff University, where I decided, in 2003, to continue my studies for my doctorate.  The body of work focussed on identifying and investigating the cancer phenotype of a novel Tsc-1 deficient model. In 2006 I started my postdoctoral research at the Experimental Cancer Genetics (Adams) lab at the Wellcome Trust Sanger Institute where I made and utilised novel models to understand the fundamental genetic mechanisms by which cancers develop. I moved to the Evan lab in 2010 to continue my work with novel switchable models to determine how tumour suppressor pathways respond to oncogenic signalling.

Current Projects: My current projects focus on using defined levels of oncogenes such as Myc and Ras in a spatial and temporal fashion in cancers. These tools and contemporary techniques have enabled unique insights into Myc-Ras cooperation in vivo. In addition, I have been lecturing to the Biochemistry Part II Cambridge undergraduates on next generation sequencing techniques and applications since 2012.

Interests: I love swimming and cycling and compete in triathlons and outdoor swimming events.


  • Rashid M, Fischer A, Wilson CH, Tiffen J, Rust AG, Stevens P, Mustonen V, Williamns G, Sampson J, David J. Adams (2016) Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: Somatic landscape and driver genes Journal of Pathology 238(1):98-108. 
  • WilsonCH, GamperI, PerfettoA, AuwJ, LittlewoodTD, Evan GI (2014) The kinetics of ER fusion protein activation in vivo. Oncogene 33(40):4877-80
  • Kerr JS and Wilson CH (2013) Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. Biochem Soc Trans 40;4:1055-1060.
  • Wilson CH, Crombie C,van der Weyden L, Poulogiannis G,Rust AG , Pardo M, Gracia T, Yu L, Choudhary J, Poulin GB, McIntyre RE, Winton D, March NH, Arends MJ,Fraser AG,Adams DJ (2012) Nuclear Receptor Binding Protein 1 (NRBP1) regulates intestinal progenitor cell homeostasis and tumor formation. EMBO J 31: 2486-2497. Previewed: Tan EH, Sansom OJ (2012) A new tumour suppressor enters the network of intestinal progenitor cell homeostasis, EMBO J 31, 2444 – 2445.
  • Naguib A, Wilson CH, Adams DJ, Arends MJ. (2010) Activation of KRAS by co-mutation of codons 19 and 20 is transforming. Journal of molecular signaling. 3;6:2.
  • Wilson CH*, McIntyre RE*, Arends MJ, Adams DJ (2010) The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice via activation of Wnt and ERK1/2 MAPK pathways. Oncogene. 12;29(32):4567-75. * Joint first author.
  • Poulogiannis G, McIntyre R, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ. (2010) PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. PNAS. 107(34):15145-50.
  • Mattison J, Kool J, Uren A, de Ridder J, Wessels L, Jonkers J,  Bignell G, Butler A, Rust A, Brosch M, Wilson CH, van der Weyden L, Largaespada D, Stratton M, Futreal A, van Lohuizen M,  Berns A, Collier L, Hubbard T, Adams DJ (2010) Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res. 1;70(3):883-95.
  • Idziaszczyk S, Wilson CH*, Smith CG, Adams DJ and Cheadle JP (2010) Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. -Cancer Genetics and Cytogenetics. 202(1):67-9. * Corresponding author.
  • UrenA, Mikkers H, KoolJ, van der WeydenL,  LundA, WilsonCH, RanceR, JonkersJ, van LohuizenM, BernsA, AdamsDJ (2009) A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc. 4(5):789-98.
  • Wilson C, Bonnet C, Guy C, Idziaszczyk S, Colley J, Humphreys V, Maynard J, Sampson JR, Cheadle JP. (2006) Tsc1-haploinsufficiency without mTOR activation is sufficient for renal cyst formation in Tsc1+/- mice. Cancer Res. 15;66(16):7934-8.
  • Patel GK, Wilson CH, Harding KG, Finlay AY, Bowden PE. (2006) Numerous keratinocyte subtypes involved in wound re-epithelialization. J Invest Dermatol. 126(2): 497-502.
  • Wilson C, Idziaszczyk S, Colley J, Humphreys V, Guy C, Maynard J, Sampson JR, Cheadle JP. (2005) Induction of renal tumorigenesis with elevated levels of somatic loss of heterozygosity in Tsc1+/- mice on a Blm-deficient background. Cancer Res. 65(22): 10179-82.
  • Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E, Bayne RA, Smith AJ, Sampson JR, Cheadle JP. (2005) A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet. 14(13): 1839-50.